Orchard Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	2017 - 2016
Net Income	-72.92	-150.66	-144.58	-151.98	-163.42	-230.5	Upgrade
Depreciation & Amortization	2.67	2.74	2.33	2	1.68	1.2	Upgrade
Share-Based Compensation	12.48	16.01	22.54	27.96	19.42	6.77	Upgrade
Other Operating Activities	-35.55	55.92	-5.38	-4.26	-23.81	124.99	Upgrade
Operating Cash Flow	-93.32	-75.99	-125.1	-126.27	-166.13	-97.54	Upgrade
Capital Expenditures	6.87	1.45	-2.13	-10.79	-4.37	-4.03	Upgrade
Change in Investments	-32.9	89.11	-29.15	168.17	-304.99	0	Upgrade
Other Investing Activities	-	-	-0.89	-	-	-	Upgrade
Investing Cash Flow	-26.02	90.56	-32.17	157.38	-309.36	-4.03	Upgrade
Share Issuance / Repurchase	68.32	0.21	157.44	3.94	133.59	209.7	Upgrade
Debt Issued / Paid	-7.86	-0.79	7.38	0	24.47	0	Upgrade
Other Financing Activities	-1.19	-0.12	-6.75	-	-0.61	145.17	Upgrade
Financing Cash Flow	59.28	-0.69	158.07	3.94	157.45	354.86	Upgrade
Exchange Rate Effect	2.73	-1.42	-0.03	1.04	1.67	-3.47	Upgrade
Net Cash Flow	-57.33	12.46	0.78	36.08	-316.36	249.83	Upgrade
Free Cash Flow	-86.44	-74.54	-127.23	-137.07	-170.5	-101.57	Upgrade
Free Cash Flow Margin	-395.82%	-329.00%	-7595.76%	-5281.93%	-6784.64%	-4892.49%	Upgrade
Free Cash Flow Per Share	-3.79	-5.82	-10.26	-13.78	-18.29	-45.02	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).